Problems in hemostasis during open heart surgery. IX. Changes observed in the plasminogen-plasmin system and their significance for therapy.
作者信息
Gans H, Castaneda A R, Subramanian V, John S, Lillehei C W
出版信息
Ann Surg. 1967 Dec;166(6):980-6. doi: 10.1097/00000658-196712000-00015.
Abstract
摘要
相似文献
1
Problems in hemostasis during open heart surgery. IX. Changes observed in the plasminogen-plasmin system and their significance for therapy.心脏直视手术中的止血问题。IX. 纤维蛋白溶酶原-纤维蛋白溶酶系统的观察变化及其对治疗的意义。
Ann Surg. 1967 Dec;166(6):980-6. doi: 10.1097/00000658-196712000-00015.
2
Previously undescribed fibrinolysis inhibitor in human blood.人类血液中以前未被描述的纤维蛋白溶解抑制剂。
Nat New Biol. 1971 Dec 8;234(49):180-1. doi: 10.1038/newbio234180a0.
3
Studies on the mechanisms of action of aprotinin and tranexamic acid as plasmin inhibitors and antifibrinolytic agents.抑肽酶和氨甲环酸作为纤溶酶抑制剂及抗纤溶药物的作用机制研究。
Blood Coagul Fibrinolysis. 1994 Aug;5(4):537-42.
4
[Investigations on the fibrinolytic activity of human urine. 3. Effect of hyperbaric oxygen on the fibrinolytic activities in blood and urine].[人体尿液纤溶活性的研究。3. 高压氧对血液和尿液中纤溶活性的影响]
Nihon Hinyokika Gakkai Zasshi. 1972 Jan;63(1):43-56. doi: 10.5980/jpnjurol1928.63.1_43.
5
Contact and plasmin kinin-forming systems in the blood.血液中的接触系统和纤溶酶激肽形成系统。
Thromb Diath Haemorrh. 1970 Dec 31;24(3):548-58.
6
Suppressed fibrinolysis after administration of low-dose aprotinin: reduced level of plasmin-alpha2-plasmin inhibitor complexes and postoperative blood loss.小剂量抑肽酶给药后纤溶功能受抑制：纤溶酶-α2-纤溶酶抑制物复合物水平降低及术后失血量减少。
Eur J Cardiothorac Surg. 1995;9(3):143-5. doi: 10.1016/s1010-7940(05)80061-2.
7
Hemostasis in patients undergoing extracorporeal circulation: the effect of aprotinin (Trasylol).体外循环患者的止血：抑肽酶（特血乐）的作用。
Thromb Haemost. 1991 Dec 2;66(6):633-7.
8
Discreplasminin, a plasmin inhibitor isolated from Tityus discrepans scorpion venom.差异纤溶酶原抑制剂，一种从差异肥尾蝎毒液中分离出的纤溶酶抑制剂。
Arch Toxicol. 2009 Jul;83(7):669-78. doi: 10.1007/s00204-008-0377-8. Epub 2008 Nov 18.
9
Discrepancies between immunological and caseinolytic plasma plasminogen assays in health and hyperfibrinolytic states.健康及高纤溶状态下免疫法与酪蛋白溶解血浆纤溶酶原检测结果的差异。
J Clin Pathol. 1974 Oct;27(10):794-7. doi: 10.1136/jcp.27.10.794.
10
Problems in hemostasis during open-heart surgery. I. On the release of plasminogen activator.心脏直视手术中的止血问题。I. 纤溶酶原激活物的释放
Ann Surg. 1961 Dec;154(6):915-24.
本文引用的文献
1
2
[Role of the contact factor (Hageman factor) in fibrinolysis].[接触因子（哈格曼因子）在纤维蛋白溶解中的作用]
Thromb Diath Haemorrh. 1959 Sep 1;3:593-603.
3
The activation of human plasminogen by streptokinase.链激酶对人纤溶酶原的激活作用。
J Biol Chem. 1955 Apr;213(2):881-91.
4
THE PLASMIN INHIBITORS OF PLASMA. I. A METHOD FOR THEIR ESTIMATION.血浆中的纤溶酶抑制剂。一、其测定方法。
Thromb Diath Haemorrh. 1964 Oct 15;12:119-25.
5
Problems in hemostasis during open-heart surgery. II. On the hypercoagulability of blood cardiac bypass.心脏直视手术中的止血问题。II. 关于体外循环时血液的高凝性。
Ann Surg. 1962 Jul;156(1):19-23. doi: 10.1097/00000658-196207000-00005.
6
Problems in hemostasis during open-heart surgery. I. On the release of plasminogen activator.心脏直视手术中的止血问题。I. 纤溶酶原激活物的释放
Ann Surg. 1961 Dec;154(6):915-24.
7
Problems in hemostasis during openheart surgery. III. Epsilon amino caproic acid as an inhibitor of plasminogen activator activity.心脏直视手术中的止血问题。III. ε-氨基己酸作为纤溶酶原激活物活性的抑制剂
Ann Surg. 1962 Feb;155(2):268-76. doi: 10.1097/00000658-196200000-00017.
8
Coagulation studies in cardiac surgery with extracorporeal circulation using a bubble-oxygenator.
Acta Chir Scand. 1959 May 31;117(1-2):47-54.
9
The mechanism of clot dissolution by plasmin.纤溶酶溶解血栓的机制。
J Clin Invest. 1959 Jul;38(7):1086-95. doi: 10.1172/JCI103885.
10
Clotting deviations in man during cardiac bypass: fibrinolysis and circulating anticoagulant.心脏搭桥手术期间人体的凝血偏差：纤维蛋白溶解与循环抗凝剂
J Thorac Surg. 1958 Oct;36(4):519-30.
Zotero 插件